Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - apraclonidine hydrochloride, quantity: 5.75 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium acetate; sodium chloride; hydrochloric acid; sodium hydroxide; purified water - to control intraocular pressure in glaucoma patients on maximally tolerated glaucoma therapy for a period of 3 months. in clinical studies the drop in intraocular pressure (iop) appeared to decrease after day 60 which may be associated with a progression of the disease or loss of effect of the drug. this phenomenon appears to be an individual occurence with a variable time of onset. as with any patient on maximally tolerated therapy (see dosage & administration), patients using apraclonidine 0.5% eye drops to delay surgery should have frequent follow-up examinations and treatment should be discontinued if iop rises significantly. in patients who have maintained a response to apraclonidine 0.5% eye drops for 3 months and a decision is made to continue treatment, safety aspects, including any evidence of corneal changes (see warnings and precautions), and iop control should be closely monitored.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

abbvie limited - levobunolol hydrochloride 0.5%{relative};  ;  ;   - eye drops, solution - 0.5 % - active: levobunolol hydrochloride 0.5%{relative}       excipient: benzalkonium chloride dibasic sodium phosphate heptahydrate disodium edetate hydrochloric acid monobasic potassium phosphate polyvinyl alcohol purified water sodium chloride sodium hydroxide sodium metabisulfite

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

allergan pharmaceuticals ireland - levobunolol hydrochloride - eye drops, solution - 0.5 percent weight/volume - beta blocking agents1); levobunolol

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

allergan pharmaceuticals ireland - levobunolol hydrochloride - eye drops, solution - 0.5 percent weight/volume - beta blocking agents1); levobunolol

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

abbvie limited - levobunolol hydrochloride - eye drops, solution - beta blocking agents1); levobunolol

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

allergan ltd - levobunolol hydrochloride - eye drops - 5mg/1ml

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

allergan new zealand ltd - levobunolol hydrochloride 0.25%{relative};  ;  ;   - eye drops, solution - 0.25 % - active: levobunolol hydrochloride 0.25%{relative}       excipient: benzalkonium chloride dibasic sodium phosphate heptahydrate disodium edetate hydrochloric acid monobasic potassium phosphate polyvinyl alcohol purified water sodium chloride sodium hydroxide sodium metabisulfite

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - levobunolol hydrochloride - eye drops - 5mg/1ml

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - levobunolol hydrochloride - eye drops - 5mg/1ml

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - levobunolol hydrochloride - eye drops - 5mg/1ml